X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds from the offering will be used to advance company's GABAB receptor with a PAM candidate for the treatment of patients with chronic cough.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2024
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
The funding will support company's metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator (NAM) program for the treatment of mild neurocognitive disorder (mNCD).
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Naason Science
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Funding September 20, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
The collaboration aims for the discovery of novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates for the treatment of substance use disorder.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $335.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration August 02, 2023
Details:
ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
This financing will support the lead product, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen, is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy.
Lead Product(s): ADX71149
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 03, 2023
Details:
ADX71149 (JNJ-40411813) is a novel orally active positive allosteric modulator of metabotropic Glutamate 2 receptor (mGlu2R). It is being developed for the treatment of epilepsy.
Lead Product(s): ADX71149,Levetiracetam
Therapeutic Area: Neurology Product Name: ADX71149
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
As part of the amended agreement, Addex retains exclusive rights to develop its own independent gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) program.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $336.0 million Upfront Cash: $5.0 million
Deal Type: Expanded Collaboration December 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
